University of California San Francisco
Immunotherapies are a promising anticancer arsenal and work by mobilizing the immune system to recognize and destroy cancer cells. Currently, however, only a third of patients respond to immunotherapies, in part because the tumour environment can be hostile to immune cells, depriving them of their source of energy, which diminishes treatment efficacy.